# A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia

> **NCT05268003** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 4 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Leukemia

## Interventions

- **DRUG:** Ponatinib
- **DRUG:** Venetoclax
- **DRUG:** Mini-hyper CVD

## Key facts

- **NCT ID:** NCT05268003
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-06-07
- **Primary completion:** 2026-04-21
- **Final completion:** 2026-04-21
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** \< 75% participation
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05268003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05268003, "A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05268003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*